Rich Pharmaceuticals' Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin's Lymphoma BEVERLY HILLS, CA , March 14, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology,...